Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Fecal Incontinence
Interventions: Consure 120 Stool Management System; Device
Lead sponsor: Consure Medical Pvt. Ltd.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Peripheral Arterial Disease
Interventions: Control/Sham Treatment, Heat Therapy (HT); Device
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Lipoma
Interventions: STARMed VIVA Combo RF System; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Enterovirus Infection
Interventions: EV68-228-N, Placebo for EV68-228-N; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Baltimore, Maryland • Nashville, Tennessee

Conditions: Blood Glucose, Blood Insulin
Interventions: Acute beverage (water) consumption, Acute beverage (Black Coffee) consumption, Acute beverage (Orange Juice) consumption, Acute beverage (Whole Milk) consumption, Acute beverage (2% Milk) consumption, Acute beverage (Skim Milk) consumption; Other
Lead sponsor: Purdue University; Other
Eligibility: 35 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Hematologic Malignancies
Interventions: Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review; Biological · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Central Serous Chorioretinopathy
Interventions: rhuFab V2 [ranibizumab] ( Lucentis ); Drug
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Fibrosis Lung, Systemic Sclerosis
Interventions: Bronchoscopy with lavage; Diagnostic Test
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: ADHD, Autism
Interventions: Very Low Dose Quillivant XR, Low Dose Quillivant XR, Moderate Dose Quillivant XR; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 5 Years to 16 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HPV Infection, HPV 16 Infection, High Risk HPV, Cervical Cancer Screening, Cervical Cancer Cin Grade, Cervical Cancer (Early Detection), HPV, HPV (Human Papillomavirus)-Associated, HPV DNA, HPV Infections, Screening Test
Interventions: Q-Pad hrHPV Test System; Device
Lead sponsor: Qurasense; Industry
Eligibility: 25 Years and older · Female only
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: New Haven, Connecticut • Minneapolis, Minnesota • Akron, Ohio

Conditions: Hydrocephalus
Interventions: Not listed
Lead sponsor: Johns Hopkins All Children's Hospital; Other
Eligibility: 1 Year to 21 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Urinary Tract Infections
Interventions: Cystoscopic Fluid containing Neosporin G. U. Irrigant, Cystoscopy, Cystoscopic Fluid/Placebo; Drug · Procedure
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Rheumatoid Arthritis
Interventions: Cimzia, Placebo; Drug
Lead sponsor: Michael Schiff, MD; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 12
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more

Conditions: De Quervain Tenosynovitis
Interventions: Intra-sheath injection, Extra-sheath injection, Ultrasound; Procedure · Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Pediatric Lumbar Puncture
Interventions: Normal Saline Intravenous Fluids; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 0 Months to 3 Months
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pneumothorax, Pleural Effusion
Interventions: No drainage threshold, Drainage <2 mL/kg; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 14 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Cancer
Interventions: U-13C-glucose; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: New Brunswick, New Jersey

Conditions: End Stage Renal Disease
Interventions: Triferic; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: ACY-1215; Drug
Lead sponsor: Acetylon Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Shigellosis
Interventions: 240 µg Shigella flexneri 2a Invaplex 50 vaccine, 480 µg Shigella flexneri 2a Invaplex 50 vaccine, 690 Shigella flexneri 2a Invaplex 50 vaccine, Shigella challenge strain; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • Silver Spring, Maryland

Conditions: Healthy
Interventions: Sotatercept, Sotatercept Autoinjector; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 4
States / cities: Anaheim, California • Miami, Florida • South Miami, Florida + 1 more

Conditions: Healthy
Interventions: Transcutaneous vagal nerve stimulation, Breathing task; Device · Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 70 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Tasimelteon Oral Capsule, Tasimelteon Oral Suspension; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Springfield, Missouri

Search by objective public record fields.

Efficacy, Safety, and Performance Study of a Novel Device Designed to Manage Fecal Incontinence in Hospitalized Bedridden Patients With Liquid to Semi-formed Stool.

Heat Therapy to Reduce Pain and Improve Walking Tolerance

RFA for Superficial Lipomas

Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults

Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overwt/Obese Adults

IVIG for Infection Prevention After CAR-T-Cell Therapy

Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study

Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer

Strata Programmable CSF Shunt Valve Study

Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

Intra-sheath vs Extra-sheath Injection for De Quervain's Tenosynovitis

Intravenous Fluid Administration's Effect on Pediatric Lumbar Puncture

Drainage Amount for Removal of Thoracostomy Tube

Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer

Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects

Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection

A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)

Imaging Brain Fluids During Breathing

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers